It is important to emphasize that this page does not describe or endorse any specific benefits, results, or outcomes for these peptides
Read clinical review Questions GIP/GLP-1 Dual Agonists: How to Select the Right Agent Within the Class A prescriber-level guide to GIP/GLP-1 dual agonists covering mechanism, agent selection, dosing, trial data, and clinical decision-making for weight loss, T2D, sleep apnea, and HFpEF
Comply with tax, accounting, recordkeeping, regulatory, court, and law-enforcement obligations
Fewer than half of patients remain on the weight loss medications at six months, the platform says, and most who stop regain the weight without nutrition and behavior support to back them up